Clinical Trial Update: SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating SBRT sequential CapeOX with Bevacizumab and Sintilimab as first-line treatment for metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CAPEOX
• Sintilimab (sintilimab)

Snippet

Sponsor: Huazhong University of Science and Technology | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN